News | April 21, 2010

Noncardiac Chest Pain Patients Need Better Screening

April 21, 2010 – The growing number of Americans with cardiovascular disease has caused a heightened sensitivity in the evaluation of chest pain. In a study published in the April issue of Mayo Clinic Proceedings, researchers said patients dismissed from the hospital with noncardiac chest pain continue to experience cardiac events, which may highlight a need for more aggressive cardiovascular risk factor management.

Noncardiac chest pain is defined as a substernal chest pain in the absence of significant epicardial coronary artery stenoses. Noncardiac chest pain is attributed to a variety of disorders, including gastroesophageal reflux disease (GERD), esophageal hypersensitivity, panic attack, musculoskeletal pain, and microvascular disease (cardiac syndrome).

Researchers identified 320 patients with a diagnosis of noncardiac chest pain to determine the frequency of gastrointestinal (GI) consultations and testing, and to identify the frequency of cardiac death. All patients had a hospital admission diagnosis of unstable angina, subsequent inpatient cardiac evaluation and a dismissal diagnosis of noncardiac chest pain.

The first aim of this study was to determine the frequency of GI consultation and testing. After the initial diagnosis of noncardiac chest pain, 49 percent of patients were re-evaluated in the Emergency Department at the Mayo Clinic and 42 percent underwent repeated cardiology evaluations; only 15 percent had GI consultations. In regards to GI testing, 38 percent underwent sophagogastroduodenoscopy, 4 percent underwent manometry (13 tests), and 2 percent had pH probes (six probes).

"Patients in this study received few GI consultations and underwent even fewer GI tests. Further study is needed to determine whether patients with noncardiac chest pain would benefit from more frequent GI consultations and more diverse use of GI testing modalities," says Michael Leise, M.D., co-investigator in the department of gastroenterology, Mayo Clinic.

The study's second aim was to report on overall mortality, specifically, cardiac death in patients with noncardiac chest pain. Although prognosis for patients with noncardiac chest pain is thought to be favorable, researchers found that previous data to support this view were limited. The total sample in this study did not display a significantly increased frequency of death compared with what would be expected in this community, but a substantial number of cardiac deaths occurred in a noncardiac chest pain population.

"We speculate that cardiac death in patients with noncardiac chest pain may relate to overlapping risk factors for GERD and coronary artery disease, including obesity, obstructive sleep apnea, diabetes mellitus and smoking," said Dr. Leise.

Until cardiac death in this population is better understood, he said it is important to screen for cardiac risk factors such as hypertension, hypercholesterolemia, and diabetes mellitus and aggressively manage these comorbid conditions.

Mayo Clinic Proceedings journal is published monthly by Mayo Foundation for Medical Education and Research. The journal has been published for more than 80 years and has a circulation of 130,000 nationally and internationally. Articles are available online at

For more information: www.mayoclinicproceedings.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now